Dr. Jay Martin Barrash, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 5959 West Loop S, Suite 470, Bellaire, TX 77401 Phone: 713-797-9775 Fax: 713-797-6221 |
News Archive
Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries.
The warning about possible liver-related problems with the depression drug, Cymbalta, has been expanded and doctors are being cautioned against its use in chronic liver disease patients.
The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
New research published online in the scientific journal Addiction shows that plain packaging (requiring cigarettes to be packaged in standard packages without attractive designs and imagery) may help to draw the attention of some adolescent smokers to the health warnings on the package. If so, this may in turn deter young smokers from continuing to smoke.
› Verified 9 days ago